1065 related articles for article (PubMed ID: 31053733)
21. Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O
Chang KY; Hsu TI; Hsu CC; Tsai SY; Liu JJ; Chou SW; Liu MS; Liou JP; Ko CY; Chen KY; Hung JJ; Chang WC; Chuang CK; Kao TJ; Chuang JY
Redox Biol; 2017 Oct; 13():655-664. PubMed ID: 28822335
[TBL] [Abstract][Full Text] [Related]
22. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN
J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
25. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465
[TBL] [Abstract][Full Text] [Related]
26. Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2.
Chen L; Li Z; Hu S; Deng Q; Hao P; Guo S
Cancer Chemother Pharmacol; 2022 Feb; 89(2):217-229. PubMed ID: 35039898
[TBL] [Abstract][Full Text] [Related]
27. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
[TBL] [Abstract][Full Text] [Related]
28. Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O⁶-methylguanine methyltransferase and promotes temozolomide responsiveness.
Berthois Y; Delfino C; Metellus P; Fina F; Nanni-Metellus I; Al Aswy H; Pirisi V; Ouafik L; Boudouresque F
Cancer Biol Ther; 2014 Jul; 15(7):938-50. PubMed ID: 24755707
[TBL] [Abstract][Full Text] [Related]
29. Glioblastoma Recurrence and the Role of O
Storey K; Leder K; Hawkins-Daarud A; Swanson K; Ahmed AU; Rockne RC; Foo J
JCO Clin Cancer Inform; 2019 Feb; 3():1-12. PubMed ID: 30758983
[TBL] [Abstract][Full Text] [Related]
30. PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.
Montaldi AP; Lima SCG; Godoy PRDV; Xavier DJ; Sakamoto-Hojo ET
Oncol Rep; 2020 Nov; 44(5):2275-2287. PubMed ID: 32901889
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
Cen L; Carlson BL; Pokorny JL; Mladek AC; Grogan PT; Schroeder MA; Decker PA; Anderson SK; Giannini C; Wu W; Ballman KV; Kitange GJ; Sarkaria JN
Neuro Oncol; 2013 Jun; 15(6):735-46. PubMed ID: 23479134
[TBL] [Abstract][Full Text] [Related]
32. Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation.
Grogan PT; Sarkaria JN; Timmermann BN; Cohen MS
Invest New Drugs; 2014 Aug; 32(4):604-17. PubMed ID: 24718901
[TBL] [Abstract][Full Text] [Related]
33. MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma.
Gan T; Wang Y; Xie M; Wang Q; Zhao S; Wang P; Shi Q; Qian X; Miao F; Shen Z; Nie E
Cancer Res; 2022 Nov; 82(22):4234-4246. PubMed ID: 36112059
[TBL] [Abstract][Full Text] [Related]
34. Long noncoding RNA RP11-838N2.4 enhances the cytotoxic effects of temozolomide by inhibiting the functions of miR-10a in glioblastoma cell lines.
Liu Y; Xu N; Liu B; Huang Y; Zeng H; Yang Z; He Z; Guo H
Oncotarget; 2016 Jul; 7(28):43835-43851. PubMed ID: 27270310
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y
Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182
[TBL] [Abstract][Full Text] [Related]
36. CREB-induced LINC00473 promotes chemoresistance to TMZ in glioblastoma by regulating O6-methylguanine-DNA-methyltransferase expression via CEBPα binding.
Jiang LY; Wang GH; Xu JJ; Li XL; Lin XY; Fang X; Zhang HX; Feng M; Jiang CM
Neuropharmacology; 2024 Feb; 243():109790. PubMed ID: 37981063
[TBL] [Abstract][Full Text] [Related]
37. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
[TBL] [Abstract][Full Text] [Related]
38. Exosomal circWDR62 promotes temozolomide resistance and malignant progression through regulation of the miR-370-3p/MGMT axis in glioma.
Geng X; Zhang Y; Lin X; Zeng Z; Hu J; Hao L; Xu J; Wang X; Wang H; Li Q
Cell Death Dis; 2022 Jul; 13(7):596. PubMed ID: 35817771
[TBL] [Abstract][Full Text] [Related]
39. A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma.
Zhao J; Yang S; Cui X; Wang Q; Yang E; Tong F; Hong B; Xiao M; Xin L; Xu C; Tan Y; Kang C
Neuro Oncol; 2023 May; 25(5):857-870. PubMed ID: 36272139
[TBL] [Abstract][Full Text] [Related]
40. EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.
Struve N; Binder ZA; Stead LF; Brend T; Bagley SJ; Faulkner C; Ott L; Müller-Goebel J; Weik AS; Hoffer K; Krug L; Rieckmann T; Bußmann L; Henze M; Morrissette JJD; Kurian KM; Schüller U; Petersen C; Rothkamm K; O Rourke DM; Short SC; Kriegs M
Oncogene; 2020 Apr; 39(15):3041-3055. PubMed ID: 32066879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
